Orthopedic Implants in Wyoming

Disruptive MedTech is a contract manufacturing and fulfillment partner specializing in custom, private-branded orthopedic medical devices. Based in Laramie, Wyoming, the company serves hospitals, ambulatory surgery centers (ASCs), private practice clinics, military, and veterans' administration facilities through a direct-to-hospital (D2H) model. DMTI operates as a Group Manufacturing Organization (GMO), offering end-to-end services from product design and development through manufacturing, quality assurance, assembly, testing, and market fulfillment. The company adheres to ISO 13485:2016 standards and maintains FDA compliance, with over 10,000 Mahe-branded products already FDA-approved. Core manufacturing services include contract manufacturing of marrow access and stimulation systems (SmartShot®), orthopedic implant hardware (Xtracta-Screw for Mahe Medical), tray kitting and replenishment (Accufix for Accu-Joint), and design-to-manufacturing support (PanPlasty for PanOrthopedic). Additional services include surgical tray reprocessing with full traceability and stock management, and sterile barrier packaging for medical and biotech products. The company employs statistical process controls and continuous improvement methodologies (6S philosophy) across all operations and expanded production capacity in 2024.

Accufix Surgical, Inc. is a medical device company specializing in orthopedic implants for foot and ankle treatment. The company manufactures the Accu-Joint® Implant System, an FDA-approved metatarsophalangeal (MTP) joint implant designed to treat degenerative and post-traumatic arthritis, hallux limitus, and hallux rigidus. The Accu-Joint® represents a bone-preserving alternative to traditional joint fusion procedures. Unlike resective implants that remove significant bone portions and transfer body weight to the implant, the Accu-Joint® uses patented resurfacing instruments to remove only cartilage and minimal bone (approximately 1 mm), preserving the patient's natural anatomy. Body weight remains distributed across existing bone structure rather than the implant, reducing loosening risk and preserving future treatment options. The system is intended for use with bone cement and enables weight-bearing on postoperative day one, supporting faster recovery and maintenance of joint mobility. The implant is indicated for patients with MTP joint disorders seeking to preserve motion and avoid the irreversible restrictions imposed by arthrodesis. Accufix positions its technology as a next-generation solution that maintains anatomic integrity while restoring pain-free function. The company markets directly to both patients and surgeons, providing clinical evidence, patient testimonials, and comparative educational materials demonstrating advantages over fusion and competing implant designs.